Northwestern Mutual Wealth Management
IMDX

Northwestern Mutual Wealth Management’s Insight Molecular Diagnostics IMDX Stock Holding History

Northwestern Mutual Wealth Management’s Portfolio IMDX Stock Details IMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-35
Closed -$1K – 3312
2021
Q4 		$1K Buy
+35
New +$2.01K ﹤0.01% 3052

Other funds holding IMDX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Northwestern Mutual Wealth Management's IMDX Position: Q1 2022 in Review

Northwestern Mutual Wealth Management sold out of Insight Molecular Diagnostics (IMDX) in Q1 2022, closing a stake of 35 shares — an estimated $1K sold.

Northwestern Mutual Wealth Management first reported a position in IMDX in Q4 2021 and held it in 1 quarter. The position peaked at $1K in Q4 2021. 86 funds tracked by Wall St. Rank hold IMDX as of Q1 2022.

  • Northwestern Mutual Wealth Management reported no remaining Insight Molecular Diagnostics position as of Q1 2022 after selling out during the quarter.
  • Northwestern Mutual Wealth Management sold 35 Insight Molecular Diagnostics shares in Q1 2022, an estimated $1K.
  • Northwestern Mutual Wealth Management first reported a position in Insight Molecular Diagnostics in Q4 2021 and held it in 1 quarter.
  • Northwestern Mutual Wealth Management's Insight Molecular Diagnostics position peaked at $1K in Q4 2021.
  • 86 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q1 2022.

Based on Northwestern Mutual Wealth Management's 13F filing for Q1 2022, filed 9 May 2022.